Background: Liver cirrhosis is the most advanced stage of chronic liver disease. Its prevalence is in increasing and it is associated with multiple etiologies. A significantly higher percentage of acute decompensated cirrhotic patients develop in-hospital mortality. Identifying patients with worse prognosis would facilitate early management of potentially severe cases. Inflammation and tissue injury increased PTX3 in the injured liver and, accordingly, circulating PTX3 was induced in patients with chronic liver diseases, and has a positive predictive value for adverse clinical outcomes. Objective: To study Pentraxins3 levels in Egyptian cirrhotic patients. Patients and Methods: The study was performed on 40 adult Egyptian patients collected from the Internal Medicine Department at Sayed-GalalAl-AzharUniversityHospital. Additionally, 20 healthy subjects were also included as control group. The study was carried out during the period from May 2018 to October 2020.Sixty Egyptian patients were divided into three equal groups: Group I patients with acute decompensation of liver cirrhosis, Group II stable cirrhotic patients, and Group III healthy subjects as controls (age and sex matched). Results: There was male predominance in the studied subjects (533%). The mean age of the studied subjects was 44.25 years with 76.6% above 40 years. There was a significant increase of AST, ALT, ALP, T. bilirubin, D. bilirubin and CRP among the stable cirrhotic and the acute liver decompensation cirrhotic compared with the controls.Pentraxin-3 was found significantly higher in acute liver decompensation cirrhotic group than control and stable cirrhotic group. It was 2.7 ± 0.7 in acute liver decompensation cirrhotic, 2.4±0.5 in stable cirrhotic and 1, 2 ± 0.2in control group. Conclusion: Patients with acute liver decompensation cirrhosis showed increased level of Pentrxin-3than in control and stable cirrhotic.